Last updated on January 2020

Paclitaxel Trastuzumab and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer


Brief description of study

This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab is a form of "targeted therapy" because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Monoclonal antibodies, such as pertuzumab, may interfere with the ability of cancer cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab may kill more tumor cells.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve the progression-free survival (PFS), as assessed by investigator using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo in patients with newly documented HER2-positive measurable metastatic breast cancer.

SECONDARY OBJECTIVES:

I. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve the overall survival (OS) relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

II. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve the overall objective response (OR), assessed by investigator using RECIST 1.1 criteria, relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

III. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve PFS, OR, and/or duration of objective response assessed by retrospective blinded central review using RECIST 1.1 criteria, relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

IV. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will decrease the incidence of subsequent brain metastases in patients without known brain metastases at study entry relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

V. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will contribute to increased patient-reported fatigue in comparison to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

VI. To determine the utility of PD-L1 immunohistochemistry (IHC) staining as a predictive and prognostic biomarker associated with clinical response, as assessed by investigator using RECIST 1.1 criteria, to atezolizumab in combination with paclitaxel, trastuzumab, and pertuzumab.

VII. To determine the immune-related toxicity profile of the two treatment regimens.

VIII. To determine the cardiac safety profile of the two treatment regimens.

EXPLORATORY OBJECTIVES:

I. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve the progression-free survival and overall objective response, assessed by investigator using immune-modified RECIST (iRECIST) criteria, relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

II. To identify potential biomarkers that can predict benefit from the addition of atezolizumab in patients with newly documented HER2-positive measurable metastatic breast cancer treated with a regimen of paclitaxel, pertuzumab, and trastuzumab, and placebo.

III. To explore the toxicity profile of the two treatment regimens using patient-reported symptomatic adverse events in addition to standard adverse event reports.

IV. To determine the feasibility and added value of frequent assessment of toxicity using Patient Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) with electronic(e)PRO reporting.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive pertuzumab intravenously (IV) over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36, and atezolizumab IV over 60 minutes on days 1 and 22. Cycles for pertuzumab, trastuzumab and atezolizumab repeat every 6 weeks and treatment with paclitaxel repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional 3 cycles of paclitaxel in the absence of progression at the investigator's discretion.

ARM II: Patients receive pertuzumab, trastuzumab, and paclitaxel as in Arm I. Patients also receive placebo IV over 60 minutes on days 1 and 22. Cycles for pertuzumab, trastuzumab, and placebo repeat every 6 weeks and treatment with paclitaxel repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional 3 cycles of paclitaxel in the absence of progression at the investigator's discretion.

After completion of study treatment, patients are followed up every 3 months for 3 years and then every 6 months for 4 years.

Clinical Study Identifier: NCT03199885

Find a site near you

Start Over

Mary Bird Perkins Cancer Center

Baton Rouge, LA United States
  Connect »

Woman's Hospital

Baton Rouge, LA United States
  Connect »

MetroHealth Medical Center

Cleveland, OH United States
  Connect »

Presbyterian Kaseman Hospital

Albuquerque, NM United States
  Connect »

Ingalls Memorial Hospital

Harvey, IL United States
  Connect »

Illinois CancerCare-Bloomington

Bloomington, IL United States
  Connect »

Illinois CancerCare-Carthage

Carthage, IL United States
  Connect »

Illinois CancerCare-Galesburg

Galesburg, IL United States
  Connect »

Illinois CancerCare-Princeton

Princeton, IL United States
  Connect »

Adena Regional Medical Center

Chillicothe, OH United States
  Connect »

Grant Medical Center

Columbus, OH United States
  Connect »

Doctors Hospital

Columbus, OH United States
  Connect »

OhioHealth Mansfield Hospital

Mansfield, OH United States
  Connect »

Marietta Memorial Hospital

Marietta, OH United States
  Connect »

Licking Memorial Hospital

Newark, OH United States
  Connect »

Southern Ohio Medical Center

Portsmouth, OH United States
  Connect »

Crossroads Cancer Center

Effingham, IL United States
  Connect »

Saint Francis Medical Center

Cape Girardeau, MO United States
  Connect »

Saint Joseph Mercy Hospital

Ann Arbor, MI United States
  Connect »

Saint Joseph Mercy Brighton

Brighton, MI United States
  Connect »

Saint Joseph Mercy Canton

Canton, MI United States
  Connect »

Saint Joseph Mercy Chelsea

Chelsea, MI United States
  Connect »

Hope Cancer Clinic

Livonia, MI United States
  Connect »

Saint Mary Mercy Hospital

Livonia, MI United States
  Connect »

Beebe Health Campus

Rehoboth Beach, DE United States
  Connect »

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, MN United States
  Connect »

Northside Hospital

Atlanta, GA United States
  Connect »

Caro Cancer Center

Caro, MI United States
  Connect »

Ascension Saint Joseph Hospital

Tawas City, MI United States
  Connect »

Capital Region Southwest Campus

Jefferson City, MO United States
  Connect »

Bozeman Deaconess Hospital

Bozeman, MT United States
  Connect »

Shenandoah Oncology PC

Winchester, VA United States
  Connect »

Virginia Cancer Institute

Richmond, VA United States
  Connect »

Katmai Oncology Group

Anchorage, AK United States
  Connect »

Geauga Hospital

Chardon, OH United States
  Connect »

UHHS-Westlake Medical Center

Westlake, OH United States
  Connect »

Randolph Hospital

Asheboro, NC United States
  Connect »

Cone Health Cancer Center

Greensboro, NC United States
  Connect »

Bryn Mawr Hospital

Bryn Mawr, PA United States
  Connect »

Riddle Memorial Hospital

Media, PA United States
  Connect »

Paoli Memorial Hospital

Paoli, PA United States
  Connect »

Lankenau Medical Center

Wynnewood, PA United States
  Connect »

Vidant Oncology-Kenansville

Kenansville, NC United States
  Connect »

Vidant Oncology-Kinston

Kinston, NC United States
  Connect »

Vidant Oncology-Richlands

Richlands, NC United States
  Connect »

Avera Cancer Institute

Sioux Falls, SD United States
  Connect »

Carle on Vermilion

Danville, IL United States
  Connect »

Carle Cancer Center

Urbana, IL United States
  Connect »

Margaret R Pardee Memorial Hospital

Hendersonville, NC United States
  Connect »

Kaiser Permanente-Anaheim

Anaheim, CA United States
  Connect »

Kaiser Permanente-Baldwin Park

Baldwin Park, CA United States
  Connect »

Kaiser Permanente-Bellflower

Bellflower, CA United States
  Connect »

Kaiser Permanente-Fontana

Fontana, CA United States
  Connect »

Kaiser Permanente - Harbor City

Harbor City, CA United States
  Connect »

Kaiser Permanente-Irvine

Irvine, CA United States
  Connect »

Kaiser Permanente-Cadillac

Los Angeles, CA United States
  Connect »

Kaiser Permanente - Panorama City

Panorama City, CA United States
  Connect »

Kaiser Permanente-Riverside

Riverside, CA United States
  Connect »

Kaiser Permanente-San Marcos

San Marcos, CA United States
  Connect »

Kaiser Permanente-Woodland Hills

Woodland Hills, CA United States
  Connect »

Weisberg Cancer Treatment Center

Farmington Hills, MI United States
  Connect »

Gulfport Memorial Hospital

Gulfport, MS United States
  Connect »

Saint Joseph Hospital East

Lexington, KY United States
  Connect »

Kaiser Permanente-Fremont

Fremont, CA United States
  Connect »

Kaiser Permanente-Fresno

Fresno, CA United States
  Connect »

Memorial Medical Center

Modesto, CA United States
  Connect »

Kaiser Permanente-Modesto

Modesto, CA United States
  Connect »

Kaiser Permanente-Oakland

Oakland, CA United States
  Connect »

Kaiser Permanente-Richmond

Richmond, CA United States
  Connect »

Kaiser Permanente-Roseville

Roseville, CA United States
  Connect »

Kaiser Permanente-San Francisco

San Francisco, CA United States
  Connect »

Kaiser Permanente San Leandro

San Leandro, CA United States
  Connect »

Kaiser San Rafael-Gallinas

San Rafael, CA United States
  Connect »

Kaiser Permanente-Santa Rosa

Santa Rosa, CA United States
  Connect »

Kaiser Permanente-South San Francisco

South San Francisco, CA United States
  Connect »

Kaiser Permanente-Stockton

Stockton, CA United States
  Connect »

Kaiser Permanente-Vallejo

Vallejo, CA United States
  Connect »

Kaiser Permanente-Walnut Creek

Walnut Creek, CA United States
  Connect »

UCHealth Greeley Hospital

Greeley, CO United States
  Connect »

Norwalk Hospital

Norwalk, CT United States
  Connect »

Sacred Heart Hospital

Pensacola, FL United States
  Connect »

Piedmont Hospital

Atlanta, GA United States
  Connect »

Piedmont Fayette Hospital

Fayetteville, GA United States
  Connect »

Baptist Health Louisville

Louisville, KY United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

Academic Hematology Oncology Specialists

Grosse Pointe Woods, MI United States
  Connect »

Allegiance Health

Jackson, MI United States
  Connect »

West Michigan Cancer Center

Kalamazoo, MI United States
  Connect »

Sparrow Hospital

Lansing, MI United States
  Connect »

Bhadresh Nayak MD PC-Sterling Heights

Sterling Heights, MI United States
  Connect »

United Hospital

Saint Paul, MN United States
  Connect »

OptumCare Cancer Care at Oakey

Las Vegas, NV United States
  Connect »

Cleveland Clinic Foundation

Cleveland, OH United States
  Connect »

ProHealth D N Greenwald Center

Mukwonago, WI United States
  Connect »

McLaren-Greater Lansing

Lansing, MI United States
  Connect »

McLaren-Port Huron

Port Huron, MI United States
  Connect »

Mission Hospital

Asheville, NC United States
  Connect »

McLaren Cancer Institute-Macomb

Mount Clemens, MI United States
  Connect »

Hennepin County Medical Center

Minneapolis, MN United States
  Connect »

United Hospital Center

Bridgeport, WV United States
  Connect »

Cleveland Clinic-Weston

Weston, FL United States
  Connect »

Hillcrest Hospital Cancer Center

Mayfield Heights, OH United States
  Connect »

North Coast Cancer Care

Sandusky, OH United States
  Connect »

South Pointe Hospital

Warrensville Heights, OH United States
  Connect »

M D Anderson Cancer Center

Houston, TX United States
  Connect »

Munson Medical Center

Traverse City, MI United States
  Connect »

University Pointe

West Chester, OH United States
  Connect »